Smad7 is a key negative regulator of the TGF-β signaling pathway; specifically, it inhibits the TGF-β and NF-κB pathways, limits RA development, and maintains the balance between Th17 cells and Tregs (119). The gene discussed is TGFB1; the disease is rheumatoid arthritis.